Envoy Medical, Inc. (COCH) - Form 8-K Summary
Business Context and Reporting Period
Envoy Medical, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on November 14, 2024. The filing serves to announce the Company's financial results for the third fiscal quarter ended September 30, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is referenced but not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing. The document solely references the issuance of a press release containing the third-quarter results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that Section and shall not be incorporated by reference into any other filings. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2024) for actual revenue, net income, and cash flow figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols for Class A Common Stock (COCH) and Redeemable Warrants (COCHW) on The Nasdaq Stock Market LLC.
- Check the exercise price of the Redeemable Warrants, noted as $11.50 per share.